KRX 131
Latest Information Update: 21 Dec 2018
At a glance
- Originator Keryx Biopharmaceuticals
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alopecia
Most Recent Events
- 13 Dec 2018 Akebia Therapeutics merged with Keryx Pharmaceuticals to form Akebia Therapeutics
- 28 Nov 2007 Discontinued - Preclinical for Alopecia in Israel (unspecified route)
- 07 Jan 2004 No development reported - Preclinical for Alopecia in Israel (unspecified route)